Elicit: Mechanism of Ocrelizumab in B-Cell Depletion
Mechanism of Ocrelizumab in B-Cell Depletion
How does ocrelizumab target CD20-positive B cells to drive B-cell depletion?
Ocrelizumab binds to CD20 on B cells and drives their depletion primarily through antibody-dependent cellular cytotoxicity mediated by monocytes via Fcγ receptor pathways, achieving rapid and sustained reduction of circulating B cells while also depleting CD20-positive T-cell subsets.
Abstract
Ocrelizumab is a humanized anti-CD20 monoclonal antibody that targets the same CD20 epitope as rituximab but achieves B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) rather than complement-dependent cytotoxicity (CDC). The antibody was engineered with amino acid modifications to enhance binding to Fcγ receptor IIIa, resulting in two- to five-fold greater ADCC activity compared to rituximab. Monocytes serve as the dominant effector cells mediating B-cell depletion through FcγRI and FcγRIII-dependent pathways, achieving rapid onset within hours and near-complete depletion (>95%) of circulating B cells by week 2. However, depletion efficiency varies across anatomical compartments, with secondary lymphoid organs retaining resistant B-cell subpopulations and bone marrow showing the weakest reduction. Ocrelizumab also co-depletes CD20-positive T-cell subsets and novel dual-expressor lymphocytes expressing both T-cell and B-cell receptors.
B-cell recovery begins in bone marrow and spleen before appearing in blood, with median time to repletion of 72 weeks. The phenotype of reconstituting B cells varies by immunological context: in settings with ongoing antigen stimulation, recovery is characterized by expansion of differentiated, myelin-reactive B cells, whereas absence of stimulation favors naive B-cell reconstitution. Treatment induces secondary immunological changes including increased BAFF levels and decreased sTACI, which may enhance regulatory plasma cell development and contribute to therapeutic efficacy. The ADCC-predominant mechanism provides more sustained depletion than CDC-predominant antibodies while potentially offering better tolerability.
Methods
We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.
- CD20 Targeting: Extract detailed information about how ocrelizumab targets CD20-positive B cells.
- Cytotoxic Mechanisms: Extract all mechanisms by which ocrelizumab induces B-cell death after CD20 binding.
- Depletion Patterns: Extract detailed patterns of B-cell depletion caused by ocrelizumab.
- Depletion Kinetics: Extract timing and kinetics of B-cell depletion and recovery with ocrelizumab.
- Molecular Determinants: Extract molecular and structural features of ocrelizumab that influence its mechanism of action.
- Comparative Mechanisms: Extract direct comparisons of ocrelizumab’s mechanism to other anti-CD20 antibodies.
Results
Characteristics of Included Studies
| Study | Full text retrieved? | Study focus | Key features |
|---|---|---|---|
| J. Uchida et al., 2004 | Yes | Mouse model of anti-CD20 therapy | Developed mouse anti-mouse CD20 antibody panel to study B-cell depletion mechanisms |
| B. Cree et al., 2025 | Yes | Review of anti-CD20 antibody evolution | Comprehensive comparison of ocrelizumab, ofatumumab, ublituximab, and rituximab |
| Pacheco-Fernández et al., 2018 | No | In vitro CDC comparison | Compared ofatumumab and ocrelizumab CDC activity using B-cell lines |
| Samantha Ho et al., 2023 | Yes | B-cell regulating factors | Examined effects on BAFF-APRIL system over 2.5 years |
| Schneider-Hohendorf et al., 2025 | No | B- and T-cell receptor repertoires | Analyzed adaptive immune changes in 35 MS patients on ocrelizumab |
| Alice Willison et al., 2025 | Yes | Immune cell dynamics comparison | Compared ocrelizumab (n=34) and ofatumumab (n=25) with flow cytometry |
| A. Bar-Or et al., 2021 | Yes | Clinical perspectives review | Detailed molecular and pharmacological attributes of four anti-CD20 antibodies |
| Darius Häusler et al., 2018 | Yes | EAE model of B-cell recovery | Characterized B-cell depletion and reconstitution in murine MS model |
| S. A. Kornilov et al., 2024 | No | Multi-omic characterization | Analyzed plasma proteome, metabolome, and lipidome changes in 14 RRMS patients |
| Prajita Paul et al., 2025 | No | Dual-expressor lymphocytes | Identified novel TCR/IgM dual-expressor cells susceptible to anti-CD20 therapy |
Mechanisms of CD20 Targeting and B-cell Depletion
CD20 Binding Characteristics
Ocrelizumab is a humanized anti-CD20 monoclonal antibody that binds to the same epitope on the large extracellular loop of CD20 as rituximab. The antibody is classified as a type I anti-CD20 agent capable of crosslinking CD20 tetramers. Enhanced binding to low-affinity variants of Fcγ receptor IIIa distinguishes ocrelizumab from rituximab, contributing to its enhanced effector function. The antibody was specifically engineered through amino acid modifications in its Fc region to increase antibody-dependent cellular cytotoxicity (ADCC) activity.
Cytotoxic Mechanisms
Ocrelizumab depletes B cells through multiple cytotoxic pathways, with ADCC as the primary mechanism. The antibody exhibits two- to five-fold greater ADCC activity compared to rituximab, while demonstrating three- to five-fold lower complement-dependent cytotoxicity (CDC) activity. Both ocrelizumab and ofatumumab can induce ADCC and CDC, though ofatumumab demonstrates stronger CDC effects, particularly at low CD20 expression levels. In vitro comparisons using human B-cell lines revealed that ocrelizumab induced less cell lysis through CDC compared to ofatumumab.
Patterns of B-cell Depletion
B-cell Subpopulations
Ocrelizumab targets CD20-positive B cells, resulting in significant reductions across multiple B-cell subsets including naive B cells, memory B cells, transitional B cells, and plasmablasts. Plasma cells, which lack CD20 expression, remain resistant to depletion, as do CD20-negative B-cell precursors and hematopoietic stem cells.
Non-B-cell Targets
Beyond conventional B cells, ocrelizumab co-depletes CD20-positive T-cell subsets. Significant reductions occurred in double-negative (CD3+CD4−CD8−) T cells, which express higher CD20 levels compared to CD4 or CD8 positive T cells.
Anatomical Compartments
B-cell depletion occurs across multiple anatomical compartments but with varying efficiency. In blood, depletion is nearly complete, with more than 95% reduction in circulating B cells. However, B cells in lymphatic organs and the CNS are not depleted to the same extent as those in blood. Secondary lymphoid organs including the spleen and lymph nodes retain a subpopulation of CD20-positive B cells resistant to depletion.